6月10日，三生制药盘中上涨5.32%，报16.23港元/股，成交额2.88亿港元。
消息面上，6月8日公司董事长兼首席执行官娄竞以每股15.2497港元增持51.6万股，总金额约786.88万港元，增持后持股比例达21.03%，释放管理层信心信号。此前股价曾触及52周新低15.50港元，董事长在低位增持对市场情绪形成提振。同时，新一轮国家医保目录调整工作全面启动，公司此前凭借PD-1/VEGF双抗SSGJ-707与辉瑞达成15亿美元前端付款的出海授权合作，创新药管线价值获市场重新关注。此外，公司已授权董事可购回不超过已发行股本10%的股份，为股价提供进一步支撑。
（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.